Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy

Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy

Thumbnail Image
Download
Name

Chen_Sensitizing protective.pdf

Size

2.65 MB

Format

Adobe PDF

Checksum (MD5)

9e600e6450037e150e7fde002f387ba0

Author(s)
Pallasch, Christian
•
Leskov, Ilya B.
•
Vorholt, Daniela
•
Drake, Adam
•
Bent, Eric H.
•
Schwamb, Janine
•
Iliopoulou, Bettina P.
•
Kutsch, Nadine
•
van Rooijen, Nico
•
Frenzel, Lukas P.
more
Date Issued
January 2014
Journal
Cell
Publisher
Elsevier
Citation
Pallasch, Christian P., Ilya Leskov, Christian J. Braun, Daniela Vorholt, Adam Drake, Yadira M. Soto-Feliciano, Eric H. Bent, et al. “Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy.” Cell 156, no. 3 (January 2014): 590–602. © 2014 Elsevier Inc.
Version
Final published version
Abstract
Therapy-resistant microenvironments represent a major barrier toward effective elimination of disseminated malignancies. Here, we show that select microenvironments can underlie resistance to antibody-based therapy. Using a humanized model of treatment refractory B cell leukemia, we find that infiltration of leukemia cells into the bone marrow rewires the tumor microenvironment to inhibit engulfment of antibody-targeted tumor cells. Resistance to macrophage-mediated killing can be overcome by combination regimens involving therapeutic antibodies and chemotherapy. Specifically, the nitrogen mustard cyclophosphamide induces an acute secretory activating phenotype (ASAP), releasing CCL4, IL8, VEGF, and TNFα from treated tumor cells. These factors induce macrophage infiltration and phagocytic activity in the bone marrow. Thus, the acute induction of stress-related cytokines can effectively target cancer cells for removal by the innate immune system. This synergistic chemoimmunotherapeutic regimen represents a potent strategy for using conventional anticancer agents to alter the tumor microenvironment and promote the efficacy of targeted therapeutics.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
http://hdl.handle.net/1721.1/96265
DOI of Published Version
https://doi.org/10.1016/j.cell.2013.12.041
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.